Blissett Deirdre B, Attvall Stig, Hellmund Richard A
MedTech Economics Ltd., Winchester, UK.
Diabetes, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Diabetes Ther. 2021 Aug;12(8):2179-2193. doi: 10.1007/s13300-021-01099-7. Epub 2021 Jul 7.
The objective of this analysis was to estimate the costs associated with using flash glucose monitoring with optional alarms as a replacement for either traditional continuous glucose monitoring (CGM) or routine self-monitoring of blood glucose (SMBG) in adults with diabetes and impaired awareness of hypoglycaemia (IAH) who use intensified insulin therapy, from a Swedish payer perspective, applying assumptions to simulate hypothetical scenarios.
A simple two-state cohort Markov model was used to calculate the cost per patient treated over a 3-year period, capturing the risk of severe hypoglycaemic events requiring medical assistance and non-adherence using quarterly Markov cycles. The costs considered were those for glucose monitoring and resource use to treat severe hypoglycaemic events. Cost inputs were sourced from Swedish price lists, manufacturer data and resource use reported in the control arm of the HypoDE study. Targeted literature searches were run in PubMed to source the clinical inputs. Uncertainty in the model was considered through one-way sensitivity analysis and scenario analysis.
Over 3 years, flash monitoring with optional alarms resulted in potential cost-savings of Swedish krona (SEK) 7708 and SEK 69,908 per patient when compared to routine SMBG or CGM respectively. Sensitivity and scenario analyses were largely supportive of this conclusion with respect to SMBG, and large cost-savings were consistent across all sensitivity and scenario analyses with respect to CGM.
Utilizing flash monitoring with optional alarms is potentially a cost-saving treatment strategy compared to routine SMBG or traditional CGM in adults with diabetes using intensive insulin and IAH from a Swedish payer perspective. Future studies in the IAH population will help to assess more precisely the relative cost impact of flash glucose monitoring with optional alarms compared with SMBG and traditional CGM.
本分析的目的是从瑞典医保支付方的角度,通过假设模拟不同场景,估算在使用强化胰岛素治疗且存在低血糖意识障碍(IAH)的成年糖尿病患者中,使用带有可选警报功能的闪光葡萄糖监测替代传统的持续葡萄糖监测(CGM)或常规自我血糖监测(SMBG)所产生的成本。
采用简单的两状态队列马尔可夫模型,计算3年期间每位患者的治疗成本,通过每季度的马尔可夫循环来捕捉需要医疗救助的严重低血糖事件风险和不依从情况。所考虑的成本包括葡萄糖监测成本以及治疗严重低血糖事件的资源使用成本。成本数据来源于瑞典价格清单、制造商数据以及HypoDE研究对照组报告的资源使用情况。通过在PubMed上进行针对性文献检索获取临床数据。通过单向敏感性分析和情景分析来考虑模型中的不确定性。
在3年期间,与常规SMBG或CGM相比,使用带有可选警报功能的闪光监测分别可为每位患者节省7708瑞典克朗(SEK)和69908瑞典克朗。敏感性分析和情景分析在很大程度上支持了与SMBG相比的这一结论,并且在所有敏感性分析和情景分析中,与CGM相比均能实现大幅成本节省。
从瑞典医保支付方的角度来看,对于使用强化胰岛素且存在IAH的成年糖尿病患者,与常规SMBG或传统CGM相比,使用带有可选警报功能的闪光监测可能是一种节省成本的治疗策略。未来针对IAH人群的研究将有助于更精确地评估与SMBG和传统CGM相比,带有可选警报功能的闪光葡萄糖监测的相对成本影响。